Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

(Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday to their lowest since August 2021, extending recent losses to ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo Nordisk on Tuesday said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and LifeMD to expand access to the blockbuster treatment now that it is ...